appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Orchid Pharma Ltd
ORCHPHARMA
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Orchid Pharma Limited, formerly Orchid Chemicals & Pharmaceuticals Limited, is a pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bulk actives, formulations and nutraceuticals.
Investor PresentationView older
View Older PresentationsPeersCompare with peers
Sun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Increased Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has increased by 1.74%
Recent NewsAll news
Orchid Pharma rises 4% on deal with Cipla to roll out new UTI drug in India
3 weeks ago•Business Standard
Orchid Pharma partners with Cipla for pan-India distribution of Cefepime-Enmetazobactam
3 weeks ago•Business Standard
Orchid Pharma partners with Cipla to launch antibiotic drug - Cefepime-Enmetazobactam in India
4 weeks ago•Business Standard
Orchid Pharma join hands with Cipla to launch new antibiotic in India
4 weeks ago•Business Standard
Orchid Pharma Gets Green Light From DCGI For New Antibiotic Drug
1 month ago•Bloomberg Quint
Orchid Pharma Q4 Results Review - Foray Into Branded Formulations: Systematix
1 month ago•Bloomberg Quint
Recent EventsAll events
Press Release
Orchid Pharma Limited has informed the Exchange regarding a press release dated Jun 28, 2024, titled "Orchid Pharma partners with Cipla to launch antibiotic Cefepime-Enmetazobactam in India". | Download
Orchid Pharma Limited has informed the Exchange regarding a press release dated Jun 28, 2024, titled "Orchid Pharma partners with Cipla to launch antibiotic Cefepime-Enmetazobactam in India". | Download
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant